Abstract:Objective: To evaluate the efficacy and safety of 24-week cyclic administration of estetrol (E4) (15 mg)/drospirenone (DRSP) (3 mg) in Japanese patients with endometriosis. Design: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Setting: Twenty-five study centers in Japan. Patient(s): A total of 162 Japanese women diagnosed with endometriosis. Intervention(s): Participants were randomly allocated to the E4/DRSP group or the placebo group. In the E4/DRSP group, participants were orally administered one tablet containing E4 (15 mg) and DRSP (3 mg) daily for 24 days, followed by one placebo tablet for 4 days for a hormone-free interval, constituting a 1-cycle regimen. One placebo tablet was administered once daily for 28 days to participants in the placebo group. The treatments were continued for six cycles (24 weeks) throughout the confirmatory period. Main outcome measure(s): Changes in visual analogue scale (VAS) scores for the most severe pelvic pain (lower abdominal and back pain) from baseline to six treatment cycles at the end of the confirmatory study period. Result(s): Estetrol/drospirenone showed changes in the mean VAS scores for the most severe pelvic pain (-33.2 mm) from baseline to the end of the 6-cycle treatment. The between-group difference was significant (-8.5 mm; 2-sided 95% confidence interval, -16.1 to -0.9 mm), showing superiority to placebo. The responder rates, ≥30% and ≥50% reductions in the VAS scores from baseline, were higher in the E4/DRSP group than in the placebo group: 53.2% vs. 29.6% and 36.4% vs. 12.3%. Objective gynecological findings (induration of the cul-de-sac, pelvic tenderness, and limited uterine mobility) were significantly improved by E4/DRSP treatment, and the proportions of stable and worsened participants were significantly lower than in the placebo group. Estetrol/drospirenone decreased the size of endometriomas and improved quality of life, on the basis of quality of life-related questionnaires and global impression scores. No safety concerns were observed with E4/DRSP treatment. Few differences were observed in the proportion of participants with hemostasis parameters outside the reference range between the E4/DRSP and placebo groups. Conclusion(s): Estetrol/drospirenone effectively treats endometriosis-associated pain and improves gynecological findings. Estetrol/drospirenone may be a safe, new option for endometriosis treatment with a potentially decreased risk of thromboembolic events. Clinical trial registration number: jRCT2011210027.

Estetrol Inhibits Endometriosis Development in an In Vivo Murine Model

Role of Mast Cells in Estrogen-Mediated Experimental Endometriosis in Rats

Abstract #1504468: Estrogen Attenuates Ferroptosis Via Estrogen Receptor (ER) Β/erα/lipocalin 2 Pathway in Endometriosis

Effect of PRL-3 inhibitor on the ectopic lesions in rats with endometriosis

The Targeted Delivery of Interleukin 4 Inhibits Development of Endometriotic Lesions in a Mouse Model

Effect of estetrol, a selective nuclear estrogen receptor modulator, in mouse models of arterial and venous thrombosis

Impact of Estetrol Combined with Drospirenone on Blood Coagulation and Fibrinolysis in Patients with Endometriosis: A Multicenter, Randomized, Open-Label, Active-Controlled, Parallel-Group Study

Lipoxin A4 Regulates Expression of the Estrogen Receptor and Inhibits 17Β-Estradiol Induced P38 Mitogen-Activated Protein Kinase Phosphorylation in Human Endometriotic Stromal Cells

Lipoxin A4 Suppresses Estrogen-Induced Epithelial-Mesenchymal Transition Via ALXR-Dependent Manner in Endometriosis

Efficacy and safety of the combination of estetrol 15 mg/drospirenone 3 mg in a cyclic regimen for the treatment of endometriosis-associated pain and objective gynecological findings: a multicenter, placebo-controlled, double-blind, randomized study

Effect of Recombinant Human Endostatin on Endometriosis in Mice

The estrogen metabolites 2-methoxyestradiol and 2-hydroxyestradiol inhibit endometriotic cell proliferation in estrogen-receptor-independent manner

Therapeutic Effect of Letrozole in Rats with Endometriosis

THE SUPPRESSIVE EFFECT OF CELASTROL ON GROWTH OF ENDOMETRIOSIS IN VITRO IS ASSOCIATED WITH ANTAGONISM OF ESTROGEN RECEPTOR ACTIVITY

15-Epi-lipoxin A4 inhibits the progression of endometriosis in a murine model

Basal and steroid hormone-regulated expression of CXCR4 in human endometrium and endometriosis

Igf-I Stimulates Er Beta And Aromatase Expression Via Igf1r/Pi3k/Akt-Mediated Transcriptional Activation In Endometriosis

The inhibitory effect of 15-R-LXA4 on experimental endometriosis.

SR‐16234, a Unique Selective Estrogen Receptor Modulator, Suppressed Proliferation and Pain‐Related Factor Expression by Inhibition of the Nuclear Factor‐kappa B Pathway in Endometriotic Stromal Cells

The copper chelator ammonium tetrathiomolybdate inhibits the progression of experimental endometriosis in TNFR1-deficient mice

Enriched Environment Decelerates the Development of Endometriosis in Mouse